Aug 13, 2013 - 10:51 am
this might be of interest to people being treated with herceptin who are HER2 positive. all the best danièle:
trial at Memorial Sloan Kettering NYC A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
at yale cancer center
here is another trial at yale cancer center Phase II-III study to Evaluate the Efficacy and Safety of T-DM1 versus. Taxane in HER-2 positive Gastric Cancer and Gastroesophageal Cancer
Conditions Adenocarcinoma of the Gastroesophageal Junction | Gastric Cancer What is the purpose of this trial? Trastuzumab emtansine is an investigational drug being studied by F. HoffmannLa Roche Ltd (Roche) and Yale Cancer Center for treating advanced gastric cancer. Trastuzumab emtansine is composed of a chemotherapeutic agent (DM1) linked to Herceptin® (trastuzumab), a monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer) that attaches to protein called HER2 on cancer cells. Trastuzumab emtansine has caused cancer cells to die in laboratory studies and has slowed tumor growth in animal studies. In clinical trials, some patients given trastuzumab emtansine experienced tumor shrinkage. Trastuzumab emtansine is produced by Roche. The use of trastuzumab emtansine in this research study is experimental, which means that it is not approved for the treatment of HER2 positive advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.